BRAIN Biotech Target price 2025 - Analyst rating & recommendation
BRAIN Biotech Classifications & Recommendation:
BRAIN Biotech Price Target
| Target Price | €5.30 |
| Price | €2.33 |
| Potential |
127.64%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target BRAIN Biotech 2026 .
The average BRAIN Biotech target price is €5.30.
This is
127.64%
register free of charge
€8.40
260.52%
register free of charge
€4.55
95.06%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend BRAIN Biotech to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BRAIN Biotech stock has an average upside potential 2026 of
127.64%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 55.50 | 57.82 |
| 1.30% | 4.19% | |
| EBITDA Margin | -7.06% | 5.07% |
| 422.89% | 171.78% |
5 Analysts have issued a sales forecast BRAIN Biotech 2025 . The average BRAIN Biotech sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an BRAIN Biotech EBITDA forecast 2025. The average BRAIN Biotech EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | -0.51 | -0.16 |
| 34.21% | 68.63% | |
| P/E | negative |
6 Analysts have issued a BRAIN Biotech forecast for earnings per share. The average BRAIN Biotech EPS is
This results in the following potential growth metrics and future valuations:
Current BRAIN Biotech Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| EQUI.TS |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 28 2025 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Jun 18 2025 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | May 30 2025 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | May 29 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | May 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 28 2025 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Jun 18 2025 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
May 30 2025 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
May 29 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
May 28 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
